WACO, Texas, April 25, 2016 /PRNewswire/ -- Allergan plc
(NYSE: AGN), a leading global pharmaceutical company, today broke
ground on a $200 million expansion of
its Waco, Texas facility. The
expansion will add 322,000 square feet of manufacturing space to
the current facility, nearly doubling its current footprint. Once
completed, the expansion is expected to add approximately 100
full-time jobs, with the potential for the expanded operations
adding as many as 250 full-time jobs as the facility reaches full
utilization. New positions that will be added include chemists,
microbiologists, process engineers and production and maintenance
technicians.
Experience the interactive Multimedia News Release here:
http://www.multivu.com/players/English/7818951-allergan-waco-tx-expansion/
Additionally, the facility expansion will upgrade the Company's
manufacturing capabilities and capacity. The expansion will add a
new raw material dispensary, an automated bulk formulation suite
and ten new state-of-the-art production lines as well as
warehousing space. Upon completion, the Waco facility will be capable of producing
more than 40 different product formulations and will increase its
production capacity by more than 50 percent.
The construction, commissioning and validation of the facility
expansion and production processes are expected to be completed by
2020. Allergan's Waco facility is
the Company's flagship manufacturing facility for its leading eye
care products, including Restasis®, Lumigan®,
Combigan®, Refresh Plus®, Refresh
Tears® and Latisse®.
"Today's groundbreaking marks an important milestone for
Allergan, strengthening our commitment to our people, operations
and the partnership we have built with Waco and the Central
Texas communities for 27 years," said Brent Saunders, President and CEO of Allergan.
"This investment will add highly-skilled jobs to the Waco and Central
Texas economies, elevate our manufacturing capabilities and
increase our ability to provide more complex medicines to more
physicians and their patients around the globe.
As we celebrate this expansion today, it is important to
remember that it was achieved through great collaboration between
Allergan and the local Waco and
Texas state governments and
chambers who have been great partners in providing a positive
business climate for our success. It is through these open
collaborations that companies like Allergan can continue to succeed
in providing important products, needed innovation and highly
skilled jobs for Texas and the
U.S. economy," added Saunders.
"I applaud Allergan for their continued commitment to
Waco, and this expansion which
will create important new jobs for highly skilled Texas workers in our growing life sciences
industry," said Texas Lieutenant Governor Dan Patrick. "I am confident that Texas' extraordinary business climate and our
commitment to growing industries like the life sciences will
continue to attract healthcare industry leaders like Allergan to
the Lone Star State."
"As a member of Congress, I have worked to ensure that our
federal laws and policies equip the private sector with the
resources and flexibility necessary to be at the forefront of
medical innovation for individuals living with serious illnesses
and conditions," said U.S. Congressman Michael C. Burgess, M.D. (R-TX). "As a country,
we must maintain our commitment to creating a positive business
environment that attracts the best and brightest to invest in
innovation—this requires providing a competitive corporate tax
policy, transparent and consistent regulation, and a strong and
skilled workforce able to help produce complex medical products. If
we are successful in doing these things, we can strengthen our
economy and improve the lives of all Americans. I am pleased that
Allergan has decided to invest its best and brightest to advance
innovation in Texas."
In addition to today's groundbreaking, Tom Kelly, Ph.D., Baylor Center for Business
& Economic Research in Baylor's Hankamer School of Business provided
a supplement to his previous economic impact analysis, "The
Economic Impact of Allergan on the Central Texas Economy," to
capture the impact of the expansion. Dr. Kelly's economic impact
analysis supplement1 found:
- Including multiplier effects, the expansion will add
$380 million to the Central Texas economy during the construction
period.
- During the first year of construction the total economic impact
of Allergan capital investment plus operations on the Central Texas economy is projected to increase
to $522.3 million from a previously
projected $450.3 million in
2016.
- During the remainder of the construction period the average
annual economic impact of new capital investment will increase to
$72 million per year.
- Upon completion of the capital expansion, Allergan's annual
economic impact on the Central
Texas economy will be $461.3
million compared with the previously projected $407.2 million per year
"This supplement continues to underscore the clear economic
and job-creating value Allergan has and will continue to provide to
both the Waco and Central Texas economies. We hope that Allergan
serves as a benchmark for other companies looking for a business
friendly community with a highly skilled workforce to consider
relocating operations to Waco and
the Central Texas area," said
Tom Kelly, Ph.D., Baylor Center for
Business & Economic Research.
Full-text of the original report and the supplement is
available via the following links:
January 2016 Economic Impact
Study:
http://allergan-web-cdn-prod.azureedge.net/actavis/actavis/media/allergan-pdf-documents/pdf-documents/allergan-baylor-university-study-jan-2016_1.pdf
April 2016 Economic Impact
Study Supplement:
http://allergan-web-cdn-prod.azureedge.net/actavis/actavis/media/allergan-pdf-documents/pdf-documents/allergan-baylor-study-update_expansion_4-2016.pdf
About Allergan's Waco, TX
Operations
Allergan employs more than 750 highly skilled
workers at its 400,000 square-foot facility located on a 69-acre
campus in Waco's Texas Central
Park. The facility currently produces a number of eye-care and
dermatological products, including Restasis®
(Cyclosporine Ophthalmic Emulsion) 0.05%, a treatment that helps
increase the eyes' natural ability to produce tears, which may be
reduced by inflammation due to Chronic Dry Eye, and
Latisse® (bimatoprost ophthalmic solution) 0.03%, an
FDA-approved treatment to grow eyelashes for people with inadequate
or not enough lashes. Allergan opened its Waco facility in 1989, and in 2016, the
Company began a substantial expansion of the facility to add a new
testing laboratory and additional production capacity to meet the
growing demand for its products around the world.
About Allergan
Allergan plc (NYSE: AGN),
headquartered in Dublin, Ireland,
is a unique, global pharmaceutical company and a leader in a new
industry model—Growth Pharma. Allergan is focused on
developing, manufacturing, and commercializing innovative branded
pharmaceuticals, high-quality generic and over-the-counter
medicines, and biologic products for patients around the world.
Allergan markets a portfolio of best-in-class products that
provide valuable treatments for the central nervous system, eye
care, medical aesthetics, gastroenterology, women's health,
urology, cardiovascular and anti-infective therapeutic categories,
and operates the world's third-largest global generics business,
providing patients around the globe with increased access to
affordable, high-quality medicines. Allergan is an industry leader
in research and development, with one of the broadest development
pipelines in the pharmaceutical industry and a leading position in
the submission of generic product applications globally.
With commercial operations in approximately 100 countries,
Allergan is committed to working with physicians, health care
providers, and patients to deliver innovative and meaningful
treatments that help people around the world live longer, healthier
lives.
For more information, visit Allergan's website at
www.allergan.com.
Forward-Looking Statement
Statements contained in
this press release that refer to future events or other
non-historical facts are forward-looking statements that reflect
Allergan's current perspective of existing trends and information
as of the date of this release. Except as expressly required by
law, Allergan disclaims any intent or obligation to update these
forward-looking statements. Actual results may differ materially
from Allergan's current expectations depending upon a number of
factors affecting Allergan's business. These factors include, among
others, the difficulty of predicting the timing or outcome of FDA
approvals or actions, if any; the impact of competitive products
and pricing; market acceptance of and continued demand for
Allergan's products; difficulties or delays in manufacturing; and
other risks and uncertainties detailed in Allergan's periodic
public filings with the Securities and Exchange Commission,
including but not limited to Allergan's Annual Report on Form 10-K
for the year ended December 31, 2015
(certain of such periodic public filings having been filed under
the "Actavis plc" name). Except as expressly required by law,
Allergan disclaims any intent or obligation to update these
forward-looking statements.
1 Supplementary analysis results based
on initial estimate of 100 additional jobs added
post-expansion.
CONTACTS:
|
Media:
|
|
Mark
Marmur
|
|
(973)
906-1526
|
|
|
|
Investors:
|
|
Lisa
DeFrancesco
|
|
(862) 261-7152
|
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/allergan-breaks-ground-on-200-million-waco-facility-expansion-300256959.html
SOURCE Allergan